Schizophrenia/Psychosis

The trial aims to investigate the positive, negative, and cognitive domains of schizophrenia.

From mild cognitive impairment and serotonin system degeneration to an update on pimavanserin for negative symptoms of schizophrenia, here are highlights from the week in Psychiatric Times.

More than a gut feeling? Researchers investigated associations between the gut microbiome and treatment resistance in schizophrenia.

Pimavanserin failed to achieve the primary efficacy endpoint of control of negative symptoms in patients with schizophrenia in the ADVANCE-2 trial. Acadia Pharmaceuticals will not pursue further research.

Check out this case study to learn more about how viral infections might play a role in triggering psychotic disorders.

From personality disorders and common comorbidities to the effects of abortion bans on mental health, here are highlights from the week in Psychiatric Times.

What is new in research on ADHD?

The CRL cited several areas for clinical improvement necessary for future approval of the treatment.

Agitation, possibly leading to aggression, is a major issue in emergency centers. Explore a case of agitation in the emergency department.

What is new in research on schizophrenia?

Here are some updates from the world of psychiatry throughout the month of January.

To divide or not to divide? Researchers compared clinical features, side effects, and blood levels between once daily versus divided clozapine dosing regimens.

The experts weighed in on a wide variety of psychiatric issues for the January 2024 issue of Psychiatric Times.

The candidate also aims to address neurodevelopmental and neurodegenerative disorders such as Parkinson disease and Rett syndrome.

From clinician wellness to THC use in adolescents, here are highlights from the week in Psychiatric Times.

Examine a case of an adolescent with psychosis that seemed to develop during chemotherapy treatment.

From substance use disorders in physicians to new research on the efficacy of MDMA-assisted therapy for PTSD, here are highlights from the week in Psychiatric Times.

RADAR trial finds more relapses when reducing than maintaining antipsychotic, but no difference in social functioning at 2 years.

Here's an update on which medications are on the horizon for the treatment of schizophrenia and PTSD.

Knowing the difference between one condition and another is critical, even when the precise diagnosis is unclear.

The abysmal conditions in state mental hospitals in the 1940s were caused by 3 factors, none of which are now true. Let’s explore.

From a groundbreaking new launch for PTSD in the United States to connections between antidepressant treatment and metabolic syndrome, here are highlights from the week in Psychiatric Times.

“If approved, KarXT would represent a new mechanism of action to treat schizophrenia, which would be the first new mechanism potentially in decades.”

New positive pivotal phase 3 study data released on oral weekly risperidone for schizophrenia.

The data assess the extended efficacy of the treatment for up to 4 years.

The device is currently under clinical trial investigation as an adjunct treatment to standard of care therapy for experiential negative symptoms of schizophrenia.

New study results show evenamide as an add-on to antipsychotics for treatment-resistant schizophrenia significantly reduced disease severity.

The experts weighed in on a wide variety of psychiatric issues for the December 2023 issue of Psychiatric Times.

Here are highlights from some of the year’s top features in Psychiatric Times from throughout 2023.